Ignite Creation Date:
2024-05-06 @ 9:25 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02978898
Status:
COMPLETED
Last Update Posted:
2016-12-01
First Post:
2016-08-29
Brief Title:
CD180 Overexpression in Follicular Lymphoma
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
CD180 Overexpression in Follicular Lymphoma Is Restricted to the Lymph Node Compartment
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BackgroundAltered Toll-like receptor TLR expression levels andor mutations in its signaling pathway such as MyD88 mutation contribute to the pathogenesis of lymphoproliferative disorders LPD CD180 is an orphan member of the TLR family that modulates the signaling of several TLRs but only limited studies have evaluated its expression by flow cytometry FCM in LPD
Methods Using a multiparameter FCM approach biologists have assessed CD180 mean fluorescence intensity MFI in lymph nodes LNs and peripheral blood PB samples obtained from patients with follicular lymphoma FL LNPB n44n15 chronic lymphocytic leukemia CLL n26n21 mantle cell lymphoma MCL n13n17 and marginal zone lymphoma MZL n16n12 Specimens from non-tumoral PB and LN n8n12 were used as controls
Methods Using a multiparameter FCM approach biologists have assessed CD180 mean fluorescence intensity MFI in lymph nodes LNs and peripheral blood PB samples obtained from patients with follicular lymphoma FL LNPB n44n15 chronic lymphocytic leukemia CLL n26n21 mantle cell lymphoma MCL n13n17 and marginal zone lymphoma MZL n16n12 Specimens from non-tumoral PB and LN n8n12 were used as controls
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None